Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509189 | 0.94 | CA2 (0.42) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL2304371 | 0.92 | CA2 (0.55) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL2305289 | 0.92 | CA2 (0.55) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL473755 | 0.92 | CA2 (0.59) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL22471739 | 0.86 | CA2 (0.56) | CA2CA1MAPK1FAAHZDHHC7 | |
| SCHEMBL18204386 | 0.86 | CA2 (0.47) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL28982556 | 0.86 | CA2 (0.47) | CA2CA1MAPK1FAAHPRKCA | |
| SCHEMBL1274961 | 0.85 | CA2 (0.59) | CA2CA1MAPK1FAAHZDHHC7 | |
| SCHEMBL1490741 | 0.85 | CA2 (0.59) | CA2CA1MAPK1FAAHZDHHC7 | |
| SCHEMBL535672 | 0.85 | CA2 (0.59) | CA2CA1MAPK1FAAHZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736840-A2 | LACTOBACILLUS PLANTARUM FOR SKIN CARE | Symrise AG (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12576018-B2 | Active agents for skin and hair care with sensory modifying properties | SYMRISE AG (DE) | 2026-03-17 | — | — | US | disclosed |
| US-12350357-B2 | Active agents for skin and hair care with physicochemical modifying properties | SYMRISE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| US-12274775-B2 | Fatty acid esters as anti-Malassezia agents | SYMRISE AG (DE) | 2025-04-15 | — | — | US | disclosed |
| EP-4487838-A2 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | Symrise AG (DE) | 2025-01-08 | — | — | EP | disclosed |
| EP-4114354-B1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2024-12-11 | — | — | EP | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230118435-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20220142885-A1 | FATTY ACID ESTERS AS ANTI-MALASSEZIA AGENTS | SYMRISE AG (DE) | 2022-05-12 | — | — | US | disclosed |
| US-8647651-B2 | Synergistic mixtures of C6- to C12-alkanediols and tropolone (derivatives) | SYMRISE AG (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2589291-A1 | Synergistically active ternary anti-microbial mixtures | Symrise AG (DE) | 2013-05-08 | — | — | EP | disclosed |
| EP-1959975-B1 | BLACKBERRY LEAF EXTRACT AS AN ACTIVE INGREDIENT AGAINST SKIN IRRITATIONS AND INFLAMMATIONS | SYMRISE AG (DE) | 2013-03-27 | — | — | EP | disclosed |
| EP-2100593-B1 | Ternary mixtures with increased collagen synthesis | SYMRISE AG (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110152383-A1 | COMPOSITIONS COMPRISING BENZYL ALCOHOL DERIVATIVES AND FURTHER ANTIMICROBIAL ACTIVE COMPOUNDS | SYMRISE AG (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2100593-A1 | Ternary mixtures with increased collagen synthesis | Symrise GmbH & Co. KG (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090162305-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | SYMRISE GMBH & CO. KG (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-1816998-B1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | SYMRISE GMBH & CO KG (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20070059331-A1 | SYNERGISTIC MIXTURES OF C6- TO C12-ALKANEDIOLS AND TROPOLONE (DERIVATIVES) | SYMRISE GMBH & CO. KG (DE) | 2007-03-15 | — | — | US | disclosed |
| US-20070054967-A1 | SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) | SYMRISE GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | HPD, CYP4A22, PAH | CA2 3108/4885CA1 3718/4885MAPK1 2746/4885 |
| US-12576018-B2 | Active agents for skin and hair care with sensory modifying properties | SCD5, SMURF1, SGMS1 | CA2 1568/4885CA1 2588/4885MAPK1 2503/4885 |
| US-20070054967-A1 | SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) | NR1H3, NR1H2, CBR3 | CA2 3436/4885CA1 3547/4885MAPK1 1543/4885 |
| US-20070059331-A1 | SYNERGISTIC MIXTURES OF C6- TO C12-ALKANEDIOLS AND TROPOLONE (DERIVATIVES) | CBR3, CBR1, CYP3A7 | CA2 1790/4885CA1 3676/4885MAPK1 2584/4885 |
| US-20090162305-A1 | FORMULATIONS OF LOW OIL CONTENT COMPRISING DIPHENYLMETHANE DERIVATIVES | TYR, CYP51A1, DDT | CA2 3951/4885CA1 4165/4885MAPK1 922/4885 |
| US-20110152383-A1 | COMPOSITIONS COMPRISING BENZYL ALCOHOL DERIVATIVES AND FURTHER ANTIMICROBIAL ACTIVE COMPOUNDS | UNC93B1, ECI1, IL4I1 | CA2 1219/4885CA1 2558/4885MAPK1 3444/4885 |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | OAT, PIGS, HLA-A | CA2 3716/4885CA1 4503/4885MAPK1 4294/4885 |
| US-20230118435-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | CUTA, ABCG2, MMP7 | CA2 4302/4885CA1 4718/4885MAPK1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.